ON
🔍
← Back to feed
FranceTechnology10 days ago

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Takeda’s Zasocitinib has shown significant superiority over Deucravacitinib in a head-to-head Phase 3 psoriasis study, suggesting it could redefine expectations for oral treatments.

2 reports

Agence France-Presse (AFP)State / PublicCenter10 days ago
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Takeda’s Zasocitinib has shown significant superiority over Deucravacitinib in a head-to-head Phase 3 psoriasis study, suggesting it could redefine expectations for oral treatments.

Bias read (Center): The article reports on a clinical trial outcome without taking a stance or using biased language. It focuses on the medical findings rather than any political or ideological perspective.

Agence France-Presse (AFP)State / PublicCenter10 days ago
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Takeda’s Zasocitinib has shown significant superiority over Deucravacitinib in a head-to-head Phase 3 psoriasis study, suggesting it could redefine expectations for oral treatments.

Bias read (Center): The article reports on a clinical trial outcome without taking a stance or using biased language. It focuses on the medical findings rather than any political or ideological perspective.